DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with Hunter syndrome (MPS II).

This is an increase of 22 owner(s) or 4.95% in the last quarter. Average portfolio weight of all funds dedicated to DNLI is 0.15%, a decrease of 14.17%. Total shares owned by institutions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for ...

Investors in Denali Therapeutics Inc (Symbol: DNLI) saw new options begin trading this week, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...

Short interest in Denali Therapeutics Inc (NASDAQ:DNLI) increased during the last reporting period, rising from 7.74M to 8.69M. This put 7.06% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...